Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.53 |
| ▸ | DUT | P33316 | 11/20 | 0.51 |
| ▸ | CRBN | Q96SW2 | 2/20 | 0.50 |
| ▸ | PKM | P14618 | 1/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24263706 | 0.89 | DUT (0.55) | L3MBTL1DUTCRBNPKM | |
| SCHEMBL4348697 | 0.87 | L3MBTL1 (0.59) | L3MBTL1DUTCRBNPKMALDH1A1 | |
| SCHEMBL592080 | 0.87 | DUT (0.55) | L3MBTL1DUT | |
| SCHEMBL7181572 | 0.85 | DUT (0.54) | L3MBTL1DUT | |
| SCHEMBL8377765 | 0.83 | PKM (0.51) | L3MBTL1DUTCRBNPKMALDH1A1 | |
| SCHEMBL14861415 | 0.82 | L3MBTL1 (0.54) | L3MBTL1DUTCRBNPKMALDH1A1 | |
| SCHEMBL5024015 | 0.80 | L3MBTL1 (0.53) | L3MBTL1DUTCRBNPKMALDH1A1 | |
| SCHEMBL5024016 | 0.80 | L3MBTL1 (0.53) | L3MBTL1DUTCRBNPKMALDH1A1 | |
| SCHEMBL2983407 | 0.80 | ALDH1A1 (0.57) | L3MBTL1DUTCRBNPKMALDH1A1 | |
| SCHEMBL2990980 | 0.80 | L3MBTL1 (0.53) | L3MBTL1DUTCRBNPKMALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9382245-B2 | Compounds and methods for treating HIV infections | YALE UNIVERSITY (US) | 2016-07-05 | — | — | US | disclosed |
| US-20150105351-A1 | COMPOUNDS AND METHODS FOR TREATING HIV INFECTIONS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2015-04-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150105351-A1 | COMPOUNDS AND METHODS FOR TREATING HIV INFECTIONS | POLM, POLRMT, DHFR | L3MBTL1 879/4885DUT 19/4885CRBN 3954/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.